Head-to-head · WeighScore
Eve vs Nova MD
The verdict
Nova MD takes it — 66.9/100 to 66.3/100, but only just.
Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules. Eve is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eve | Nova MD |
|---|---|---|
| WeighScore | 66.3/100 | 66.9/100 |
| Grade | C | C |
| Scorecard rank | #189 | #174 |
| Semaglutide | $195/mo (compounded) | $175/mo (compounded) |
| Tirzepatide | $195/mo (compounded) | $225/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #189 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Graded #174 · C
Strengths
- On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
- $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
- $50 off first tirzepatide order shown publicly
- Explicit microdose / low-dose program for both semaglutide and tirzepatide
- Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1
Where it loses points
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy not named — only 'accredited facilities'
- LegitScript certification not confirmed (only 'Licensed US Providers' claims)
- Per-state availability not listed
- Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.